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Key Points
• The inhibitor incidence in
nonsevere hemophilia A
patients with certain F8
mutations approaches the
inhibitor incidence in severe
patients.
• These findings are highly
relevant for clinical practice,
as they facilitate identification
of high-risk patients based on
F8 genotype.
Neutralizing antibodies (inhibitors) toward factor VIII form a severe complication in
nonsevere hemophilia A, profoundly aggravating the bleeding pattern. Identification
of high-risk patients is hampered by lack of data that take exposure days to ther-
apeutic factor VIII concentrates into account. In the INSIGHT study, we analyzed
the association between F8 mutation and inhibitor development in patients with
nonsevere hemophilia A (factor VIII 2-40 IU/dL). This analysis included 1112 non-
severe hemophilia A patients from 14 centers in Europe and Australia that had
genotyped at least 70% of their patients. Inhibitor risk was calculated as Kaplan-
Meier incidence with cumulative number of exposure days as the time variable.
During 44 800 exposure days (median, 24 exposure days per patient; interquartile
range [IQR], 7-90), 59 of the 1112 patients developed an inhibitor; cumulative in-
cidence of 5.3% (95% confidence interval [CI], 4.0-6.6) after a median of 28 exposure
days (IQR, 12-71). The inhibitor risk at 50 exposure days was 6.7% (95% CI, 4.5-8.9)
and at 100 exposure days the risk further increased to 13.3% (95% CI, 9.6-17.0).
Among a total of 214 different F8 missense mutations 19 were associated with
inhibitor development. These results emphasize the importance of F8 genotyping in nonsevere hemophilia A. (Blood. 2013;
122(11):1954-1962)
Introduction
Patients with hemophilia A who are treated with factor VIII
concentrates are at risk of developing factor VIII neutralizing
alloantibodies (inhibitors).1,2 Inhibitor development is one of
the most challenging complications in the treatment of hemo-
philia A, as it increases the bleeding tendency while it renders
treatment with therapeutic factor VIII concentrates ineffective.
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Treatment of patients with inhibitors can be very complicated and
costly.3
Although inhibitor development is less frequently observed in
patients with nonsevere hemophilia A (baseline factor VIII activity of
2-40 IU/dL), the clinical impact can be profound. In these patients,
inhibitors may also interact with their endogenous factor VIII, re-
sulting in a decrease of the factor VIII plasma level below 1 IU/dL1
and major bleeding complications.4 Identification of patients at risk
of developing inhibitors may help to prevent this serious complica-
tion. However, currently there are no tools available to predict
individual inhibitor risk in nonsevere hemophilia patients.
The type of mutation in the factor VIII gene (F8) is an important
risk factor for inhibitor development.5-7 Nonsevere hemophilia A
is generally caused by F8 missense mutations.8 Despite informa-
tion on large numbers of F8 mutations associated with nonsevere
hemophilia A that is collected in international databases,9,10 it is
not possible to calculate the inhibitor risk for specific F8mutations,
as data on exposure days to therapeutic factor VIII concentrates are
lacking. Moreover, there may be a reporting bias in these databases
favoring registration of those with identified inhibitors.
As inhibitor development is elicited by the exposure to thera-
peutic factor VIII, the risk of developing inhibitors strongly de-
pends on the cumulative number of exposure days. Information
regarding exposure to factor VIII concentrates is especially important
in nonsevere hemophilia A patients, as they receive factor VIII re-
placement therapy on an irregular basis andmuch less frequently than
severe hemophilia A patients on account of having milder bleeding
phenotypes. Previous studies in severe hemophilia A demonstrate the
risk of developing inhibitors after more than 50 exposure days
decreases to less than 1%.1 The majority of patients with severe
hemophilia A receives 50 exposure days within the first few years
of life. However, in nonsevere hemophilia A, even some adult
patients may still have less than 50 exposure days to therapeutic
factor VIII and will thus still be at risk of developing inhibitors.
This study includes the largest cohort of patients with nonsevere
hemophilia A to assess the risk of inhibitor development. It is the
first analysis of the association between inhibitor development and
F8 mutation in nonsevere hemophilia that takes cumulative ex-
posure to therapeutic factor VIII concentrates into account. This
provides valuable data enabling a more personalized inhibitor risk
estimation, which is of immediate clinical relevance. Moreover, it
may improve our understanding of alloreactivity in response to an
intravenous protein therapeutic.
Patients and methods
Subjects and study design
This retrospective cohort study includes patients from a source population
consisting of all patients (n 5 2711) with nonsevere hemophilia A (baseline
factor VIII activity of 2-40 IU/dL) who received at least one exposure to
factor VIII concentrate between January 1, 1980 (when factor VIII concentrates
became more widely available) and January 1, 2011 in 1 of the 34 participating
hemophilia treatment centers of the INSIGHT study. Participating centers (listed
in the data supplement on the Blood Web site.) were located in 10 European
countries and Australia. The institutional review boards of all participating
centers approved the study and have indicated that signed informed consent
was not required. All patients from the source population were followed-up
from birth until death, emigration, loss-to-follow-up, or the end of the study.
This study was conducted in accordance with the Declaration of Helsinki.
Because inhibitor patients may be more likely to be genotyped, we were
concerned that inhibitor patients would be overrepresented in our cohort.
To reduce the risk of selection bias, we restricted our analysis to all patients
(n5 1112) of the centers that had genotyped at least 70% of their patients (see
flowchart of patients in Figure 1). The cutoff of>70% was arbitrarily chosen
before initial analysis. In these 14 centers, which are located in 8 countries,
patients were genotyped as part of the routine practice, independent of patient
characteristics. Patients were included in the center where they received treat-
ment with factor VIII concentrates (prior to inhibitor development). Patients
whowere referred to a participating center once they had already developed an
inhibitor were excluded from the analysis.
Data collection
Data were collected from medical records using a standardized electronic
case report form. The following data on patient characteristics were collected:
date of birth, ethnicity, F8 mutation, family history of hemophilia and
inhibitors. Additionally, we collected data on the total number of days on
which the patient was exposed to therapeutic factor VIII concentrates before
inhibitor development or the end of the follow-up period. An exposure day
Figure 1. Flowchart of patients included in the study. *Eradication treatment: ITI, immunodulating treatment or a combination of these.
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was defined as a calendar day during which 1 or more infusions of factor VIII
concentrates were administered. The cumulative number of exposure days
was classified into the following 7 categories: 1 to 5, 5 to 10, 10 to 20, 20 to
30, 30 to 50, 50 to 100, and >100 exposure days. Detailed information for
each exposure day (such as date, factor VIII product type, and reason for
treatment) were not necessary for the analysis of the association between
inhibitor development and F8 mutation, and were not collected due to
feasibility reasons.
Laboratory tests and F8 mutation analysis
Results of the following laboratory tests were collected to confirm the
diagnosis of nonsevere hemophilia A: baseline factor VIII activity (FVIII:C,
assessed by the 1-stage clotting factor VIII assay, 2-40 IU/dL), von
Willebrand factor antigen level (VWF:Ag), and von Willebrand factor
activity (VWF:RCo). Patients with FVIII:C levels ,2 IU/dL were not
included in the study to avoid misclassification and inclusion of severe
hemophilia A patients because older FVIII:C tests were less precise in
measuring the lower ranges of FVIII:C. F8 mutation was collected from
authorized genetic laboratory reports in the patient’s records or derived from
his pedigree (in 5.3% of the patients) when the causative mutation had been
identified in another family member. Standard methods for the analysis of the
F8 were used at each individual laboratory as previously described.11 Each
mutationwas reviewed and identified using the traditional nomenclature based
on the mature processed protein. Amino acid numbering for point mutations is
given for the mature processed protein, as universally used in F8 studies. To
convert to HumanGenomeVariation Society (HGVS) type of numbering, add
19 to positive numbers.12
Definition of inhibitor development
Inhibitor tests were done at the discretion of each center, and the results of all
inhibitor tests were reviewed to confirm the inhibitor status of the patients
(no data on the number of inhibitor tests performed on each patient were
available). Inhibitory antibodies were quantified at each local laboratory by
the original Bethesdamethod or the Nijmegenmodified assay from the 1990s
onwards.13,14
Only patients with a clinically relevant inhibitor were classified to be
positive for an inhibitor in the analysis. A clinically relevant inhibitor was
defined as having at least 2 positive Bethesda inhibitor assay titers of >1.0
Bethesda inhibitor assay unit per mL (BU/mL). A high titer inhibitor was
defined as a historical peak titer .5.0 BU/mL. Patients with inhibitor titers
between 0.6 and 1.0 BU/mL had to fulfill 1 of the following 2 criteria to be
classified as having a clinically relevant inhibitor: a decrease in factor VIII
plasma level to at least 50% of the baseline level, or a reduced half-life after
factor VIII administration of less than 6 hours. Patients whowere not tested for
factor VIII inhibitors during the follow-up period and who had no clinical
features of inhibitor development (eg, increased bleeding tendency) were
classified as negative for inhibitors (n 5 5).
Data analysis
To adjust for the varying number of cumulative exposure days to factor VIII
concentrates, we calculated Kaplan-Meier cumulative inhibitor incidences with
inhibitor development as the event, and the cumulative number of exposure
days as the time variable. Missing values of cumulative exposure days were
imputed using multiple linear regression methods in 4% of the patients.15 For
F8 mutations carried by .10 subjects, Kaplan-Meier cumulative inhibitor in-
cidences were interpreted as inhibitor risk and are presented as percentages
with 95% confidence interval (CI). To enable comparison of inhibitor risk be-
tween F8 mutations at a certain time point in treatment, cumulative inhibitor
incidences are given at 20 and 50 exposure days. The risk is calculated by
dividing the number of inhibitor patients with a specific mutation by the total
number of patients with the same mutation that have a certain number of
exposure days (eg, 20 or 50 exposure days). Thus, an inhibitor risk of 30% after
50 exposure days for a specific mutation means that after 50 exposure days to
therapeutic factor VIII concentrates 30% of the patients with this mutation
developed an inhibitor.
Results
Patient characteristics
In total, 1112 subjects with a confirmed diagnosis of nonsevere he-
mophilia A received 1 or more exposures to factor VIII concentrate
and were included in the study population. Patients who were born
between 1908 and 2009 were observed for approximately 25 700
patient years and 44 800 exposure days with a median follow-up of
38 years (IQR, 18-56) and 24 exposure days (IQR, 7-90) per patient.
Two-thirds of patients had fewer than 50 exposure days at the end of
follow-up (n 5 755 [68%]), with most of them (n 5 517) who had
fewer than 20 exposure days. These and other demographic char-
acteristics of the patients were comparable to that of the source
population of 2711 patients (shown in Table 1).
Inhibitor development
Inhibitors developed in 59 patients, cumulative incidence of 5.3%
(95% CI, 4.0-6.6) at a median age of 46 years (IQR, 18-65). Most
inhibitors developed in the period of 2000 to 2010 (n5 37 [64%]),
as compared with 17 inhibitors (29%) between 1990 and 1999 and
4 (7%) between 1980 and 1989. Patients who developed an inhib-
itor between 1980 and 1989 were younger at the time of inhibitor
development (1980-1989: median age at inhibitor development,
25 years [IQR, 19-60]; 1990-1999: median, 52 years [IQR, 21-66];
2000-2010: median, 47 years [IQR, 15-65]) and had less cumu-
lative exposures to factor VIII concentrates before inhibitor de-
velopment (1980-1989: median, 11 ED [IQR, 6-75]; 1990-1999:
median, 12 ED [IQR, 8-41]; 2000-2010: median, 32 ED [IQR,
Table 1. Characteristics of the total study population (n 5 1112)
Parameter n (%) or median (IQR)
Total length of observation, years 25 700
Total length of observation, ED 44 800
Baseline FVIII:C, IU/dL 11.5 (6.0-20.0)
Classified into FVIII:C categories, IU/dL
2-5 231 (20.8)
6-10 283 (25.4)
11-20 345 (31.0)
21-30 180 (16.2)
31-40 73 (6.6)
F8 genotype known 895 (80.5)
Positive family history of inhibitors 26 (2.3)
Ethnicity
White 1,049 (94.3)
African-American 14 (1.3)
Asian 18 (1.6)
Other 24 (2.2)
Unknown 7 (0.6)
Age at the end of follow-up, years 38 (18-56)
Number inhibitors 59 (5.3)
Cumulative ED to factor VIII concentrates 24 (7-90)
Classified into ED categories:
1-5 166 (14.9)
5-10 151 (13.6)
10-20 200 (18.0)
20-30 131 (11.8)
30-50 107 (9.6)
50-100 156 (14.0)
$100 179 (16.1)
Unknown 22 (2.0)
ED, exposure days to factor VIII concentrates.
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21-75 ED]). The median peak inhibitor titer was 9 BU/mL (IQR,
2-30) and 36 (61%) patients had a high titer inhibitor. Endogenous
FVIII:C was decreased in 34 (58%) inhibitor patients; FVIII:C
fell below <2 IU/dL in 20 (34%) patients, of whom 16 patients
had FVIII:C <1 IU/dL (27%). At inhibitor detection, 30 (51%)
patients had an increased bleeding tendency and 47 (80%) patients
needed treatment of bleeding when the inhibitor was present. In 11
inhibitor patients (19%) there was no clinical sign of inhibitor
development at presentation and the inhibitor was detected during
routine inhibitor testing. The inhibitor became undetectable in 42
of 59 patients (71%) after a median of 45 weeks (IQR, 13-108), and
in 12 patients (29%) after inhibitor eradication therapy (immune
tolerance induction n5 7, immunosuppressive therapy n5 4, both
n 5 1). In 30 patients (71%) the inhibitor cleared spontaneously
without specific inhibitor eradication therapy (of whom 18 were re-
challenged to factor VIII concentrates after the inhibitor became
undetectable), and in 3 patients (5%) eradication therapy was
unknown. In 14 patients (15%) the inhibitor was still present at
the end of follow-up, and in 3 patients (5%) inhibitor status at the
end of follow-up was unknown (Figure 1).
Inhibitors were detected after a median of 28 exposure days (IQR,
12-71). Forty-one patients (69%) developed an inhibitor before 50
exposure days, 17 patients (29%) between 50 and 100 exposure days,
and only 1 patient (2%) after more than 100 exposure days. The in-
hibitor risk at 20 and 50 exposure dayswas 3.5% (95%CI, 2.1-4.9) and
6.7% (95% CI, 4.5-8.9), respectively. The inhibitor risk was 13.3%
(95% CI, 9.6-17.0) in patients with 100 exposure days (Figure 2).
Patients who developed inhibitors were comparable to patients
who did not develop inhibitors regarding ethnicity (inhibitor patients,
97%white; noninhibitor patients, 95%white) and severity of disease
(inhibitor patients: median, FVIII:C, 10 IU/dL [IQR, 6-19]; non-
inhibitor patients: median, FVIII:C, 10.5 IU/dL [IQR, 6-18]).
F8 mutations
F8 genotype was known in 895 patients (81%) of the study pop-
ulation (n 5 1112) and in 51 (51 of 59 [86%]) patients who had
developed an inhibitor. In total, 214 different missense mutations
(n 5 865 patients [78%]) and 17 other mutations (n 5 30 patients
[3%]) were identified in F8 (supplemental Table 1). prevalent
amino acid substitutions were Arg593Cys (9%), Arg2150His (5%),
Asn618Ser (5%), and Arg531Cys (3%). The complete list of mu-
tations of the centers that had genotyped at least 70% of their
patients (n5 1112) and of the total INSIGHT cohort (n5 2711) are
presented in supplemental Tables 1 and 2. There was a wide variation
of baseline FVIII:C levels within patients carrying the same F8
mutation (supplemental Tables 1 and 2) that could not be explained
by interlaboratory variability or variation of FVIII:C assays over time.
There was a variation in inhibitor risk between FVIII:C levels,
however, there was no trend observed toward patients with lower
FVIII:C levels having the highest inhibitor risk (data not shown).
Association between inhibitors and F8 mutation
Nineteenmutations (Leu412Phe, Arg531Cys, Arg593Cys, Asn618Ser,
Pro1761Gln, Phe1775Val, Arg1781Gly, Pro1854Leu, Arg1997Trp,
Asp2074Gly, Phe2101Cys, Tyr2105Cys, Arg2150His, Arg2159Cys,
Glu2228Asp, Trp2229Cys,Val2232Ala,His2309Asp, Stop2333Cys)
were associated with inhibitor development and were all located in
the A2 domain of the heavy chain and in the A3, C1, and C2 domains
of the light chain of the factor VIII protein (Figure 3). These
mutations were all missense mutations in F8 and were identified
in a total of 333 patients including the 51 genotyped patients with
inhibitors. Table 2 and supplemental Table 1 summarize the num-
bers and proportions of patients with inhibitors according to the
F8 mutation. Inhibitor risk for individual F8 mutations varied
Figure 2. Cumulative inhibitor incidence in 1112 nonsevere hemophiliaA patients, according to cumulative exposure days to factor VIII concentrates.
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between 0% to 42% at 50 exposure days (Table 2). Two of the 19 F8
mutations associated with inhibitor development (Phe1775Val,
Stop2333Cys) have not been reported before in the the Haemo-
philia A Mutation, Structure, Test and Resource site or Center for
Disease Control Hemophilia A Mutation Project database and five
F8 mutations were not previously reported with inhibitor devel-
opment (Leu412Phe, Arg1781Gly, Phe2101Cys, Arg2159Cys,
His2309Asp).9,10
Discussion
This is the largest cohort of nonsevere hemophilia A patients inwhich
the inhibitor risk and its association with F8 mutations has been
assessed, taking exposure days into account. The inhibitor risk was
6.7% at 50 exposure days, rising to 13.3% at 100 exposure days. We
identified 19 mutations associated with inhibitor development (of
which 7 were not previously reported with inhibitors)– from a total of
214 different missense mutations.9,10 This information emphasizes
the importance ofF8 genotyping in nonsevere hemophilia A patients.
It also demonstrates the importance of reporting inhibitor occurrence
to either of the international databases if these are to be an important
ongoing resource for inhibitor risk assessment.16
Importantly, the risk of inhibitor development in patients with
nonsevere hemophilia approaches the risk of severe hemophilia
patients when inhibitor development is evaluated as a function of
exposure to factor VIII concentrates.1,17 This highlights the sub-
stantial risk of inhibitor development in nonsevere hemophilia A
patients that has been previously underestimated. Given that
unexposed patients were excluded from the study population, and
that a large proportion of patients (68%) included in the study had
fewer than 50 exposure days, there is a large population of un-
challenged patients who may need treatment with factor VIII con-
centrates in the future. Thus, inhibitor development in nonsevere
hemophilia A patients may become an important future burden of
care in hemophilia treatment.
As the inhibitor risk of several missense mutations approaches
that of severe patients, this may suggest that these single amino acid
mutations are highly immunogenic. Previous observations suggest
that both position and type of substitution of missense mutations
may influence the inhibitor risk. Consistent with these observations,
the mutations associated with inhibitors in the INSIGHT cohort
were all located within the regions encoding for the light chain and
the A2 domain of factor VIII.8 A recent study by Schwaab et al18
indicates that the risk of inhibitor formation is significantly higher
if the substituted amino acid in the factor VIII protein belongs to
another physicochemical class than the original residue. Our study
was epidemiological in nature and did not aim to elucidate the
immunologic mechanism underlying the association of the F8 gene
mutation and inhibitor risk. This will definitely be an important aim
for future studies in this field. There was a wide variation in inhibitor
risk between patients with different FVIII:C levels and no trend was
observed, therefore, the relation between F8 mutation and inhibitor
risk could not be explained by FVIII:C level.
An unexpected high incidence of inhibitors occurred after 50
exposure days. Development of inhibitors later in life has been
recently recognized in hemophilia A patients with prior extensive
exposure to factor concentrates.17,19 The possibility of age-related
immune dysregulation and late loss of tolerance may be particularly
relevant to the nonsevere hemophilia cohort, as exposure to
therapeutic factor VIII concentrates is distributed throughout life
and often skewed to later decades for elective operative interventions.
Current hypotheses suggest that this may be elicited by the clinical
circumstances during exposure that trigger the immune system, such
as intensive treatment with factor VIII concentrates for surgery.20,21
Although we adjusted for cumulative number of exposure days, the
present analysis does not take potential clinical risk factors (such as
factor VIII product type, intensity, and reason for treatment) into
account.19-21 However, it is highly unlikely that these clinical risk
factors have influenced the observed association betweenF8 genotype
and inhibitor development due to the principle ofMendelian randomi-
zation: inheritance of a certain genotype is “random” and will not be
influenced by environmental determinants of inhibitor development.22
When interpreting the results of this study there are certain lim-
itations that should be kept in mind. We obtained data from nonse-
vere patients that did receive treatment with factor VIII concentrates.
Patients with a very mild bleeding phenotype or those exclusively
treated with desmopressin were not included. As those who need
treatment with factor VIII concentrates do not represent all nonse-
vere hemophilia A patients, the incidence of inhibitors in the total
nonsevere hemophilia A population will be lower than reported in
our study. The applicability of our results is also limited to white
populations, as the study population was mainly white.
Only if new F8 mutations would occur at a high rate, this could
introduce confounding, as FVIII product type has also changed over
time. However, the spontaneous mutation rate in nonsevere hemo-
philia is described to be very low (5%).23 Therefore, we do not expect
this to be an important confounder in our analysis.
Because family members who share the same F8 mutation are
more likely to share allelic variants of other genes (eg, immune-
response genes [TNFA, IL-10 or CTLA-4]) that increase the risk for
inhibitor development in severe hemophilia A, we cannot exclude
that other inherited factorsmay also have contributed to the observed
associations.24-27
Theoretically there is one specific situation that may lead to a
biased estimate of the effect of F8 genotype on inhibitor risk that has
been explained in an article by Sheehan et al.28 This could occur if
there would be another gene that affects both inhibitor risk and is also
linked to theF8mutation. In this case, the second genemay confound
the association between F8mutation and disease. Currently, there are
no data on a gene linked to F8 that also causes inhibitors, but of
course this is theoretically possible. The low incidence (2.3%) of
patients with a positive family history of inhibitors in our cohort is
likely to be a function of challenges of data collection associating
a particular individual with other family members (especially when
they are treated in different centers) and emphasizes the need for
decent family tree maintenance.
Despite the large number of patients included in our study, we
acknowledge that our study has limited statistical power to calculate
the inhibitor risk formost of theF8mutations, because thesemutations
only occur in a small number of patients or because the patients with
these specific mutations have a limited number of exposure days.
However, considering the extent of this study, it may never be du-
plicated or prospectively studied. Given that inhibitors were not reg-
ularly tested in all patients after a predefined regimen, we may have
missed patientswith asymptomatic or transient inhibitors, especially in
the beginning of the observation period (1980-2000). Therefore, the
inhibitor incidences in our study may be underestimated. To reduce
the potential influence of interassay and interlaboratory variability on
inhibitor classification, we used a clinically relevant inhibitor as the
outcome measure.29
Our study identifies a higher incidence of inhibitor development
in nonsevere hemophilia than previously appreciated and has made
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Figure 3. Distribution of F8 missense mutations associated with inhibitor development. (A) Two-dimensional and (B) three-dimensional structure of the factor VIII
protein.
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the first step toward identification of high risk patients based on their
F8 genotype. As there are currently no proven strategies to prevent
inhibitor development in nonsevere hemophilia patients, further
research to develop preventive strategies is urgently needed. In the
absence of these strategies, we propose that desmopressin response
should be tested in all nonsevere hemophilia A patients to optimize
the use of desmopressin in adequate responders as an effective
and safe alternative for factor VIII concentrates, without the risk
of inhibitor development.30 This is relevant because it appears
that at least some high-risk mutations respond well to desmopressin
administration.31 Our study also highlights the potential of F8
genotyping to estimate individualized risks of inhibitor formation
for those mutations with sufficient data. It can inform the patient-
doctor consultation, contributing to the decision whether to pro-
ceed with an elective intervention and how to manage it, and may
therefore be of immediate clinical relevance. Moreover, the results
of our study contribute to our knowledge of alloreactivity in re-
sponse to an intravenous protein therapeutic.
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Table 2. Inhibitor risk of the 19 F8 mutations in which inhibitor development occurred
F8 mutation
No. of
patients
n (%)*
No. of patients
with inhibitor
n (%)
Baseline FVIII:C,
IU/dL median
(min-max)
End of
follow-up†
(Cum no. ED)
No. of patients
under observation
at 20 ED
Inhibitor risk at
20 ED‡
% (95%CI)
No. of patients
under observation
at 50 ED
Inhibitor risk
at 50 ED‡
% (95% CI)
Mutations in 10 or more patients
Arg531Cys 35 (3.2) 1 (2.9) 8 (2-37) .100 25 0.0 16 0.0§
Arg593Cys|| 106 (9.5) 12 (11.3) 17 (5-32) .100 35 9.1 (2-16) 16 18.3 (7-30)
Asn618Ser 58 (5.2) 1 (1.7) 24 (8-37) .100 18 2.9 (0-9) 5 2.9 (0-9)
Asp2074Gly 11 (1.0) 3 (27.3) 8 (4-14) .100 7 21.2 (0-47) 5 21.2 (0-47)
Arg2150His 57 (5.1) 9 (15.8) 7 (2-32) .100 36 2.2 (0-7) 20 12.2 (1-24)
Arg2159Cys 21 (1.9) 3 (14.3) 14 (6-29) .100 8 9.1 (0-26) 3 39.4 (3-75)
Trp2229Cys 10 (0.9) 5 (50.0) 8 (5-24) 50-100 4 41.7 (5-78) 3 41.7 (5-78)
Mutations in less than 10 patients
Leu412Phe 5 (0.4) 1 (20.0) 8 (3-14) .100
Pro1761Gln 2 (0.2) 1 (50.0) 6 (5-6) .100
Phe1775Val 3 (0.3) 2 (66.7) 27 (13-29) 10-20
Arg1781Gly 4 (0.4) 1 (25.0) 8 (6-16) 50-100
Pro1854Leu 4 (0.4) 1 (25.0) 14 (6-25) .100
Arg1997Trp 3 (0.3) 2 (66.7) 4 (4-6) .100
Phe2101Cys 2 (0.2) 2 (100) 7 (6-7) 50-100
Tyr2105Cys 6 (0.5) 3 (50.0) 19 (12-28) 20-30
Glu2228Asp 3 (0.3) 1 (33.3) 27 (16-36) 10-20
Val2232Ala 1 (0.1) 1 (100.0) 15 30-50
His2309Asp 1 (0.1) 1 (100.0) 2 30-50
Stop2333Cys 1 (0.1) 1 (100.0) 11 5-10
Total 333 (29.9) 51 (15.3)
*Percentage of total cohort of patients (n 5 1112).
†End of follow-up for each F8mutation is defined as the maximum number of exposure days to factor VIII concentrates observed during follow-up for at least 1 patient with
this F8 mutation.
‡The risk is calculated by dividing the number of inhibitor patients with a specific mutation by the total number of patients with the same mutation that have a certain
number of exposure days (eg, 20 or 50 exposure days).
§Inhibitor risk is 0 at 50 ED because the patient with this mutation that developed an inhibitor did so after 95 exposure days.
||One of the patients with the Arg593Cys mutation who developed an inhibitor also had a polymorphism in the promoter of the F8 gene (c.-112G . A).
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